Contraception
Volume 80, Issue 1 , Pages 95-100, July 2009

Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy☆☆☆★

  • Michel Lièvre

      Affiliations

    • Department of Pharmacology, Université Lyon 1, UMR5558, Hospices Civils de Lyon, F-69003 France
    • Corresponding Author InformationCorresponding author. Service de Pharmacologie Clinique, Faculté de médecine RTH Laennec, 69372 Lyon Cedex 08, France. Tel.: +33 0 478785759; fax: +33 0 478776917.
    • ,
  • Regine Sitruk-Ware

      Affiliations

    • Population Council and Rockefeller University, New York, NY 10065, USA

Received 24 April 2008; received in revised form 26 January 2009; accepted 26 January 2009. published online 12 March 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Exelgyn SA, a marketer of mifepristone, funded this study.

☆☆ M.L.'s institution has received a grant from Exelgyn for the meta-analysis. R.S.-W. was previously Director of Research at Exelgyn.

★ The content of this article reflects the personal views of R.S.-W. and not necessarily that of the organizations to which she is affiliated.

PII: S0010-7824(09)00032-8

doi:10.1016/j.contraception.2009.01.011

Contraception
Volume 80, Issue 1 , Pages 95-100, July 2009

Article Tools